Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/04/2003WO2003099298A1 Rna interference mediating small rna molecules
12/04/2003WO2003099297A1 Treatment of mucositis
12/04/2003WO2003099296A1 Method of treating multiple sclerosis
12/04/2003WO2003099295A1 Dual dispenser for aesthetically acceptable delivery of anhydrous skin treatment compositions
12/04/2003WO2003099294A1 Drugs improved in tissue selectivity
12/04/2003WO2003099293A1 Pharmacologically active salts
12/04/2003WO2003099292A1 Treatment of post-menopausal complaints in breast cancer patients comprising tibolone and a serm
12/04/2003WO2003099291A1 Progestagenic dosage units
12/04/2003WO2003099290A1 Pharmaceutical products and methods of manufacture
12/04/2003WO2003099289A2 Compositions and their uses for alleviating pain
12/04/2003WO2003099288A1 Medicinal composition
12/04/2003WO2003099286A1 Pyrrolotriazinone compounds and their use to treat diseases
12/04/2003WO2003099285A1 Compositions comprising hepoxilin analogs and their use in the treatment of cancer
12/04/2003WO2003099284A1 Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
12/04/2003WO2003099283A1 Method of treating actinic keratosis
12/04/2003WO2003099282A1 White matter neuroprotectant pyrroloquinoline quinone compounds and methods of use thereof
12/04/2003WO2003099281A2 Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
12/04/2003WO2003099280A1 Novel formulation for the parenteral application of crobenetine
12/04/2003WO2003099279A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003WO2003099278A1 Ophthalmological use of roflumilast for the treatment of diseases of the eye
12/04/2003WO2003099277A1 Method of reducing incidence diabetic embryopathy with l-ergothioneine
12/04/2003WO2003099275A1 Method for the use of pyranoindole derivatives to treat infection with hepatitis c virus
12/04/2003WO2003099274A1 Hepatitis c virus inhibitors
12/04/2003WO2003099273A1 Adduct of topiramate and tramadol hydrochloride and uses thereof
12/04/2003WO2003099271A1 Use of diuretics for treating swellings
12/04/2003WO2003099270A1 Methods of treating allergic reactions
12/04/2003WO2003099269A1 Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
12/04/2003WO2003099268A1 Combination of selected opioids with other active substances for use in the therapy of urinary incontinence
12/04/2003WO2003099267A1 Medicament with delayed release of the active substance, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
12/04/2003WO2003099266A2 Acetamides and benzamides that are useful in treating sexual dysfunction
12/04/2003WO2003099265A2 Pharmaceutical active substance combination and the use thereof
12/04/2003WO2003099264A1 Compositions and method for transmucosal drug delivery and cryoprotection
12/04/2003WO2003099263A1 At least partially degradable films containing an active ingredient and method for the production thereof
12/04/2003WO2003099260A1 Method for preparing polymer micelle pharmaceutical preparation containing drug for injection
12/04/2003WO2003099259A1 Oleaginous oral antiparasitic compositions
12/04/2003WO2003099258A1 Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol
12/04/2003WO2003099256A2 FREE-FLOWING, POWDERY COMPOSITION CONTAINING α-LIPONIC ACID (DERIVATIVES)
12/04/2003WO2003099247A1 Tooth whitening products
12/04/2003WO2003099231A2 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins
12/04/2003WO2003099228A2 Compositions and processes for inhibiting gene expression using polynucleotides
12/04/2003WO2003099221A2 Methods for using jnk inhibitors for treating or preventing disease-related wasting
12/04/2003WO2003099218A2 Anti-cancer formulation
12/04/2003WO2003099217A2 Methods of treating bacterial infections and diseases associated therewith
12/04/2003WO2003099215A2 Antisense modulation of glucocorticoid receptor expression
12/04/2003WO2003099214A2 Biguanide formulations
12/04/2003WO2003099212A2 Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
12/04/2003WO2003099211A2 Mitotic kinesin inhibitors
12/04/2003WO2003099203A2 Enteric coated caffeine tablet
12/04/2003WO2003099201A2 Compositions and methods of use for a fibroblast growth factor
12/04/2003WO2003099200A2 Composition and method for the treatment of diaper rash using natural products
12/04/2003WO2003099197A2 Formulations of erythromycin derivatives with improved bioavailability
12/04/2003WO2003099195A2 Immunomodulatory compounds and methods of use thereof
12/04/2003WO2003099194A2 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003WO2003099192A2 Bis-aromatic alkanols
12/04/2003WO2003099163A1 Vehicles for delivery of biologically active substances
12/04/2003WO2003099013A1 Acetaminophen/non-steroidal anti-inflamatory drug-glucosamine composition
12/04/2003WO2003099011A1 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
12/04/2003WO2003099007A1 Aqueous fludarabine phosphate composition
12/04/2003WO2003099006A1 Disinfectant with activity against hepatitis b virus
12/04/2003WO2003098992A2 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
12/04/2003WO2003090818A3 Drug-delivery endovascular stent and method for treating restenosis
12/04/2003WO2003088948A3 Microemulsions for selective molecular separation
12/04/2003WO2003088920A3 Low profile combination device for gastrostomy or jejunostomy applications having anti-granuloma formation characteristics
12/04/2003WO2003086309A3 NF-κB INHIBITORS
12/04/2003WO2003082196A3 Combination therapy using trefoil peptides
12/04/2003WO2003080629A3 Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
12/04/2003WO2003075928A3 Stable pharmaceutical compositions
12/04/2003WO2003075921A3 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
12/04/2003WO2003074550A3 Pin1-modulating compounds and methods of use thereof
12/04/2003WO2003074485A3 Indole-amide derivatives and their use as glycogen phosphorylase inhibitors
12/04/2003WO2003074002A3 Methods of treating pin1 associated disorders
12/04/2003WO2003072154A8 Composition and method for coating medical devices
12/04/2003WO2003072062A3 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
12/04/2003WO2003072057A3 Intraspinal continuous infusion of midazolam hydrochloride for the treatment of pain
12/04/2003WO2003072013A3 Novel applications of statins in dermatology and corresponding pharmaceutical formulations
12/04/2003WO2003070728A3 Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
12/04/2003WO2003070179A3 Phosphonate-phosphate and diphosphonate apolipoprotein e modulators
12/04/2003WO2003069998A8 Stable compositions comprising tezacitabine
12/04/2003WO2003068790A3 Macrolide antibacterial compounds
12/04/2003WO2003066810A3 Recombinant bovine immunodeficiency virus based gene transfer system
12/04/2003WO2003066604A3 Novel aryl- and heteroarylpiperazines
12/04/2003WO2003064596A3 Desaturase genes, enzymes encoded thereby, and uses thereof
12/04/2003WO2003063846A3 Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of cardiovascular conditions
12/04/2003WO2003063794A3 2,4-pyrimidinediamine compounds and their uses
12/04/2003WO2003062200A3 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists
12/04/2003WO2003061598A3 Solenopsin a, b and analogs as novel angiogenesis inhibitors
12/04/2003WO2003061593A3 Novel targeted compositions for diagnostic and therapeutic use
12/04/2003WO2003061579A3 Phthalocyanine and porphyrazine pharmaceutical compositions
12/04/2003WO2003061578A3 Compositions for treatment or prevention of bioterrorism
12/04/2003WO2003060468A3 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease
12/04/2003WO2003060096A3 Assay for the detection of factors that modulate the expression of ingap
12/04/2003WO2003059878A3 Thieno (3, 2-b) pyridones as antiviral compounds
12/04/2003WO2003059875A3 DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
12/04/2003WO2003059807A3 Crystalline solids of carvedilol and processes for their preparation
12/04/2003WO2003059332A3 Use of an anti-microtubule agent for the treatment of uveitis
12/04/2003WO2003057898A8 Methods and materials for modulating p2x2
12/04/2003WO2003057169A3 4-dedimethylamino tetracycline compounds
12/04/2003WO2003057145A3 SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
12/04/2003WO2003055448A3 Antifungal compositions
12/04/2003WO2003050122A3 Mitotic kinesin inhibitors
1 ... 5252 5253 5254 5255 5256 5257 5258 5259 5260 5261 5262 5263 5264 5265 5266 5267 5268 5269 5270 5271 5272 ... 7860